Neurofilament light as a biomarker in traumatic brain injury.

Acute Disease Adult Area Under Curve Atrophy Biomarkers / blood Brain / pathology Brain Concussion / blood Brain Injuries, Traumatic / blood Chronic Disease Diffuse Axonal Injury / blood Diffusion Tensor Imaging Female Hockey / injuries Humans Male Neurofilament Proteins / blood Organ Size Prospective Studies ROC Curve Recovery of Function Sweden / epidemiology United States / epidemiology Young Adult

Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
11 08 2020
Historique:
received: 29 08 2019
accepted: 07 01 2020
pubmed: 10 7 2020
medline: 21 10 2020
entrez: 10 7 2020
Statut: ppublish

Résumé

To determine whether serum neurofilament light (NfL) correlates with CSF NfL, traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) estimates of traumatic axonal injury (TAI). Participants were prospectively enrolled in Sweden and the United States between 2011 and 2019. The Swedish cohort included 45 hockey players with acute concussion sampled at 6 days, 31 with repetitive concussion with persistent postconcussive symptoms (PCS) assessed with paired CSF and serum (median 1.3 years after concussion), 28 preseason controls, and 14 nonathletic controls. Our second cohort included 230 clinic-based participants (162 with TBI and 68 controls). Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n = 30), 90 (n = 48), and 180 (n = 59) days and 1 (n = 84), 2 (n = 57), 3 (n = 46), 4 (n = 38), and 5 (n = 29) years after injury. In athletes with paired specimens, CSF NfL and serum NfL were correlated ( Serum NfL shows promise as a biomarker for acute and repetitive sports-related concussion and patients with subacute and chronic TBI. This study provides Class III evidence that increased concentrations of NfL distinguish patients with TBI from controls.

Identifiants

DOI: 10.1212/WNL.0000000000009983 PMID: 32641538 PMC: PMC7455357
pubmed: 32641538
pii: WNL.0000000000009983
doi: 10.1212/WNL.0000000000009983
pmc: PMC7455357
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0
neurofilament protein L 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e610-e622

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2020 American Academy of Neurology.

Références

EBioMedicine. 2016 May;7:287-288
pubmed: 27322482
J Neurotrauma. 2019 Apr 15;36(8):1222-1230
pubmed: 30375271
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28373358
Sci Rep. 2016 Nov 07;6:36791
pubmed: 27819296
BMJ Open Sport Exerc Med. 2016 Mar 16;2(1):e000092
pubmed: 27900166
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Lancet Neurol. 2018 Sep;17(9):782-789
pubmed: 30054151
J Neurosci. 2018 Oct 10;38(41):8723-8736
pubmed: 30143572
Psychol Med. 1973 Aug;3(3):270-303
pubmed: 4729191
AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2064-74
pubmed: 23306011
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Br J Sports Med. 2013 Apr;47(5):250-8
pubmed: 23479479
Neuroimage. 2011 Sep 15;58(2):458-68
pubmed: 21718790
Nat Med. 2019 Feb;25(2):277-283
pubmed: 30664784
J Neuropathol Exp Neurol. 2009 Jul;68(7):709-35
pubmed: 19535999
J Neurotrauma. 2019 Aug 15;36(16):2400-2406
pubmed: 30843469
Neurobiol Aging. 2017 Nov;59:1-9
pubmed: 28779628
J Neurotrauma. 2013 Jul 15;30(14):1211-22
pubmed: 23731282
Ann Neurol. 2014 Feb;75(2):277-86
pubmed: 24255008
Lancet Neurol. 2017 Dec;16(12):987-1048
pubmed: 29122524
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
J Neurotrauma. 2019 Jul 15;36(14):2178-2189
pubmed: 30760178
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Neurology. 2017 May 9;88(19):1788-1794
pubmed: 28404801
Neuroimage. 2017 Feb 1;146:132-147
pubmed: 27864083
Neurology. 2020 Aug 11;95(6):e623-e636
pubmed: 32641529
JAMA Neurol. 2016 Nov 1;73(11):1308-1315
pubmed: 27654934
J Neurotrauma. 2017 Mar 1;34(5):1124-1127
pubmed: 27539721
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Brain Res. 2017 Aug 1;1668:12-19
pubmed: 28522263
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
J Neurotrauma. 2019 May 15;36(10):1551-1560
pubmed: 30489229
Neurology. 2018 Oct 9;91(15):e1385-e1389
pubmed: 30209234
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
MMWR Surveill Summ. 2017 Mar 17;66(9):1-16
pubmed: 28301451
J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272
pubmed: 27188986

Auteurs

Pashtun Shahim (P)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK. pashtun-poh.shahim@nih.gov.

Adam Politis (A)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Andre van der Merwe (A)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Brian Moore (B)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Yi-Yu Chou (YY)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Dzung L Pham (DL)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

John A Butman (JA)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Ramon Diaz-Arrastia (R)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Jessica M Gill (JM)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

David L Brody (DL)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Henrik Zetterberg (H)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Kaj Blennow (K)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.

Leighton Chan (L)

From the NIH (P.S., A.P., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); Center for Neuroscience and Regenerative Medicine (P.S., A.v.d.M., B.M., Y.-Y.C., D.L.P., J.A.B., J.M.G., D.L.B., L.C.); The Henry M. Jackson Foundation for the Advancement of Military Medicine (P.S., A.v.d.M., B.M., J.M.G., D.L.B.), Bethesda, MD; Department of Psychiatry and Neurochemistry (P.S., H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Uniformed Services University of the Health Sciences (D.L.B.), Bethesda, MD; Department of Neurology (R.D.-A.), University of Pennsylvania, Philadelphia; UK Dementia Research Institute at UCL (H.Z.); and Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, London, UK.
ORCID: 0000-0001-9001-872X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie aigüe › Neurofilament light as a biomarker in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Neurofilament light as a biomarker in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Aire sous la courbe › Neurofilament light as a biomarker in...
questionsmedicales.fr › États, signes et symptômes pathologiques › États anatomopathologiques › Atrophie › Neurofilament light as a biomarker in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Neurofilament light as a biomarker in...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Neurofilament light as a biomarker in...
questionsmedicales.fr › Plaies et blessures › Plaies non pénétrantes › Traumatismes crâniens fermés › Commotion de l'encéphale › Neurofilament light as a biomarker in...
questionsmedicales.fr › Plaies et blessures › Traumatismes du système nerveux › Traumatismes cranioencéphaliques › Lésions encéphaliques › Lésions traumatiques de l'encéphale › Neurofilament light as a biomarker in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Neurofilament light as a biomarker in...
questionsmedicales.fr › Plaies et blessures › Traumatismes du système nerveux › Traumatismes cranioencéphaliques › Lésions encéphaliques › Lésions encéphaliques diffuses › Lésion axonale diffuse › Neurofilament light as a biomarker in...
questionsmedicales.fr › Techniques d'investigation › Neuroimagerie › Imagerie par tenseur de diffusion › Neurofilament light as a biomarker in...
questionsmedicales.fr › Activités humaines › Activités de loisirs › Loisir › Sports › Hockey › Neurofilament light as a biomarker in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Neurofilament light as a biomarker in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines neurofilamenteuses › Neurofilament light as a biomarker in...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Taille d'organe › Neurofilament light as a biomarker in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Neurofilament light as a biomarker in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Courbe ROC › Neurofilament light as a biomarker in...
questionsmedicales.fr › Phénomènes biologiques › Récupération fonctionnelle › Neurofilament light as a biomarker in...
questionsmedicales.fr › Régions géographiques › Europe › Pays nordiques et scandinaves › Suède › Neurofilament light as a biomarker in...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Neurofilament light as a biomarker in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Neurofilament light as a biomarker in...